BioRestorative Therapies logo

BioRestorative Therapies (BRTX) Q1 2026 Earnings

BRTX·Reported May 14, 2026·Before market open

BioRestorative Therapies reported Q1 2026 revenue of $23.2K (-7.3% YoY), missed analyst consensus of $312.5K by $289.3K. Diluted EPS came in at $-0.19 (+66.1% YoY), beat the $-0.20 consensus by $0.01.

Revenue
$23.2Kmissed by $289.3K
Consensus: $312.5K
Diluted EPS
$-0.19beat by $0.01
Consensus: $-0.20
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0001493152-26-023126

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about BioRestorative Therapies's Q1 2026 earnings report.

BioRestorative Therapies (BRTX) reported Q1 2026 earnings on May 14, 2026 before market open.

BioRestorative Therapies reported revenue of $23.2K and diluted EPS of $-0.19 for Q1 2026.

Revenue missed the consensus estimate of $312.5K by $289.3K. EPS beat the consensus estimate of $-0.20 by $0.01.

Compared to the same quarter a year prior, revenue declined 7.3% from $25.0K a year earlier and diluted EPS grew 66.1% from $-0.56.

You can read the 10-Q periodic report (0001493152-26-023126) directly on SEC EDGAR. The filing index links above go to sec.gov.